Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
November 13, 2017 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced today that the independent Data and Safety Monitoring Board (DSMB) for the...
Sickle Cell Disease Treatment Market to Reach US$ 584.0 Mn by 2025 – Persistence Market Research
September 26, 2017 11:18 ET
|
Persistence Market Research
New York, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Global sickle cell disease treatment market is expected to witness robust growth during the forecast period. This growth is expected to be primarily...
Global Blood Therapeutics Announces Participation at Three September Conferences
September 03, 2015 07:35 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of...
Vista Partners Publishes May 2013 Macroeconomic & Investment Newsletter
May 01, 2013 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - May 1, 2013) - Vista Partners ("Vista") announced today that it published its FREE macroeconomic/small cap oriented monthly newsletter for the month of May. Each...
Vista Partners Publishes December 2012 Newsletter
December 04, 2012 09:00 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Dec 4, 2012) - Vista Partners ("Vista") announced today that it published its FREE macroeconomic/small cap oriented monthly newsletter for the month of December....
Vista Partners Publishes November 2012 Newsletter
November 08, 2012 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Nov 8, 2012) - Vista Partners ("Vista") announced today that it published its FREE macroeconomic/small cap oriented monthly newsletter for the month of November....
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; Raises Target Price to $4.50
November 06, 2012 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Nov 6, 2012) - Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) ("ADVENTRX" or "ANX"); and raised its...